Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in ...

Meet the new Valeant: Drugmaker drops tainted name to become Bausch Health in July rebrand A buyout would be one of the largest private equity healthcare deals of the year as Bausch + Lomb has an ...

Dec 12 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health (BHC.TO ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following ...

1 Luc Bonnefoy, president of the Surgical Division at Bausch + Lomb, highlighted the importance of the acquisition, pointed out the announcement further demonstrates the company’s commitment to ...

Bausch & Lomb (NYSE:BLCO) rose 1.3% after confirming a sales process for the eyecare company. The maker of contact lenses commented on the sales process following a request from the Canadian ...

Canada-headquartered Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a ...